Whole-gland biology, from a urine sample.
The Garde Diagnostic Platform combines a standardized urine-to-sncRNA lab workflow with a supervised machine learning risk-stratification engine. One platform. Many cancers. Disease-agnostic by design.
Capture the whole gland, not 0.32% of it.
Standard prostate biopsy samples roughly 0.32% of the gland and misses disease in the rest. Garde measures 40 to 50 exosomal small non-coding RNA sequences shed by the entire gland into urine, capturing a whole-gland molecular fingerprint from a non-invasive sample.
From sample to actionable result.
A four-step pipeline that runs on the reference lab infrastructure healthcare systems already trust.
Start with urine
A standard, non-invasive urine sample. No biopsy, no needle, no catheter. Collected anywhere and shipped to a reference lab.
Extract biomarkers
A reference lab extracts, amplifies, and quantifies the biomarkers using established molecular biology techniques and standard laboratory tools.
Algorithmic analysis
A supervised machine learning model, trained on curated outcome-labeled cohorts, translates the molecular signal into a quantitative risk of clinically significant disease.
Actionable results
Garde Prostate Test results indicate which treatment pathway will best serve the patient. The test results are aligned to NCCN treatment and billing pathways.
Supervised machine learning, hosted on Garde infrastructure.
The molecular signal alone isn't a diagnosis. Clinicians need a calibrated, quantitative risk assessment that maps to existing care pathways. Garde's supervised machine learning model transforms the multi-marker sncRNA panel into a single, interpretable risk score for clinically significant disease.
Multi-signal
Built on roughly 40 to 50 biomarker sequences read in parallel, capturing whole-gland biology rather than relying on a single noisy signal.
Interpretable
Output maps directly to existing NCCN pathways. No new clinical workflow required.
Improvable
As validation cohorts grow, the model improves without re-engineering the lab workflow.
Designed for the labs healthcare systems already use.
Garde slots into the reference lab infrastructure healthcare systems already trust. Sample prep follows established molecular biology techniques. Output is delivered through standard reporting interfaces. The clinical decision flows mirror the pathways urologists already use.
- Standard collectionUrine sample, no novel hardware required for the patient or clinician.
- Reference-lab compatibleSuppliers trusted by healthcare systems globally can purchase and process the test.
- Existing care pathwaysResults route into NCCN treatment and billing pathways without disruption.
Garde owns the algorithm. The wet lab is commodity.
Want a deeper technical briefing?
For investors, clinicians, or potential collaborators evaluating the platform.